

Darzalex Faspro[®] (daratumumab/hyaluronidase-fihj) – New indication

- On July 30, 2024, the <u>FDA announced</u> the approval of <u>Johnson & Johnson's Darzalex Faspro</u> (daratumumab/hyaluronidase-fihj), for the treatment of adult patients with multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).
- Darzalex Faspro is also approved for seven other multiple myeloma indications and for light chain amyloidosis.
- The approval of Darzalex Faspro for the new indication was based on an open-label, randomized, active-controlled study in 709 patients. Patients received D-VRd or bortezomib, lenalidomide and dexamethasone (VRd). The major efficacy outcome measure was progression-free survival (PFS).
 - Treatment with D-VRd resulted in a reduction in the risk of disease progression or death by 60% vs. VRd alone (Hazard ratio, 0.40; 95% CI: 0.29, 0.57; p < 0.0001).
 - The median PFS was not reached in either arm.
- The most common adverse reactions (≥ 20%) with Darzalex Faspro and VRd use in multiple myeloma were peripheral neuropathy, fatigue, edema, pyrexia, upper respiratory infection, constipation, diarrhea, musculoskeletal pain, insomnia, and rash.
- The recommended dose of Darzalex Faspro for the treatment of the new indication is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously over approximately 3-5 minutes and in the schedule as follows:

Treatment Phase	Weeks	Schedule
	weeks 1-8	weekly (total of 8 doses)
Induction	weeks 9-16ª	every 2 weeks (total of 4 doses)
	Stop for high	dose chemotherapy and ASCT
Consolidation	weeks 1-8 ^b	every two weeks (total of 4 doses)
^a Eirst dose of the even	2 wook dooing ophodu	le is given et week 0

^a First dose of the every-2-week dosing schedule is given at week 9
^b First dose of the every-2-week dosing schedule is given at week 1 upon re-initiation of treatment following ASCT

- Refer to individual drug labels for dosage recommendations for the other drugs.
- Refer to the Darzalex Faspro drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.